Only recently, molecularly targeted therapies with EGFR (epithelial growth factor receptor) inhibitors have been applied with moderate outcomes in HNSCC indicating the need for the search of other therapeutic strategies. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.